Andrea Botticelli
@dottbotticellia
MD, PhD, assistant Professor, Sapienza University of Rome, breast cancer, Head and neck cancer, precision medicine @sapienzaroma
ID: 1637529328769433600
19-03-2023 19:00:31
71 Tweet
102 Followers
205 Following
I couldn’t be more proud of being awarded as one of the ESMO - Eur. Oncology Clinical Research Fellow 2024, which will allow me to continue my research among Ospedale San Martino Genova and Institut Jules Bordet Instituut! Deeply grateful to Matteo Lambertini, MD PhD and Evandro de Azambuja, MD, PhD for supporting me and this research proposal! 🙏🏼
Superb presentation of the Rome trial by Andrea Botticelli during the Presidential Session III at #ESMO24 🔝🇮🇹 congratulations 👏🏻 Andrea
🚨in the future of oncology with Andrea Botticelli presenting ROME trial outcome! —> using personalized target and immuno therapy in pretreated metastatic solid tumor patients improves ORR and PFS! 📈 #ESMO24 #Italianeffort ESMO - Eur. Oncology OncoAlert Sapienza Università di Roma
🎉🎉🎉Outstanding #PrecisionOncology work by Andrea Botticelli at the Presidential symposium ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors G Curigliano MD PhD Paolo Marchetti
Just presented at the #ESMO24 Presidential Symposium III by the king Andrea Botticelli a massive 🇮🇹 precision medicine effort….fantastic presentation my friend and super important data!!! #ESMOAmbassadors ESMO - Eur. Oncology OncoAlert #ItalianPride
⭐️Huge congratulations to Andrea Botticelli for the amazing presentation of the #PrecisionOncology Rome Trial at the Presidential Symposium ESMO - Eur. Oncology #ESMO24 ! This was phenomenal session overall #ESMOAmbassadors G Curigliano MD PhD Paolo Marchetti Ben Westphalen
⭐️Outstanding ESMO - Eur. Oncology ASCO special joint session co-chaired by our beloved ASCO President Robin Zon, MD, FACP, FASCO & amazing ESMO President Andres Cervantes ! What an amazing vision in putting this amazing session together. 👉🏼So honored to talk about Tumor Agnostic Drug development &
🔥Final presidential day! #ESMO24 Molecular tumour board #MTB playing a crucial role in a tumour agnostic way. MTB is routine National Cancer Centre Singapore. Let me know if your institute does it too! A definite way forward! 🙌🏼 Daniel Tan #precisiononcology #personalisedmedicine
⭐️It was such a great honor to talk about “Tumor-Agnostic Biomarker Driven Drug development: How & How often?” at the special joint session of ASCO & ESMO - Eur. Oncology meeting #ESMO24 #ESMOAmbassadors ! ⭐️Grateful to our beloved ASCO President Robin Zon, MD, FACP, FASCO & amazing ESMO President
Engaging presentations at #Presidential Symposium III: Eyes to the Future at #ESMO24 w/Andrea Botticelli Cigall Kadoch Adrian Sacher, M.D. FabriceAndre Nadia Harbeck,MD PhD. Thx ESMO - Eur. Oncology for the opportunity to discuss the PIOneeR trial by Pascale Tomasini & team. We need more biomarker driven and
‼️34 Posts Not to Miss From ESMO24 Day 4‼️ 🔍From precision oncology breakthroughs to new standards in TNBC treatment—insights shaping the future of cancer care! ESMO - Eur. Oncology oncodaily.com/insight/145039 Vivek Subbiah, MD Andrea Botticelli Ravindran Kanesvaran Penilla Gunther SIOPE 🎗️ SIOG
Presenting the Rome trial results at ESMO - Eur. Oncology 24 Presidential Session - Andrea Botticelli G Curigliano MD PhD oncodaily.com/blog/144886 #Cancer #ESMO24 #OncoDaily #Oncology #Medicine #MedEd #MedNews #MedX #Health
☀️Bright and early‼️ 🚨Just recorded a LIVE NEWS segment on cutting-edge oncology progress 👉🏼team tagging with world-renowned breast cancer expert Dr. Erika Hamilton Erika Hamilton, MD for NewsNation ! 👉🏼Stay tuned for the link #DynamicDuo Sarah Cannon Docs SCRI Oncology Partners #Oncology
🚨Good morning !!! Such a delight to share the latest & greatest breakthroughs in cancer NewsNation LIVE NEWS segment team tagging with world-renowned Breast Cancer expert Erika Hamilton, MD Sarah Cannon Docs SCRI Oncology Partners Link: newsnationnow.com/morninginameri…
🌟 #ESMO24 | ONCOLOGÍA DE PRECISION 🌟 El Dr. Andrea Botticelli Andrea Botticelli presentó el innovador "Rome Trial", que evalúa tratamientos personalizados para cáncer avanzado o metastásico, basados en alteraciones genéticas del tumor. 🔬 Este estudio utiliza perfiles
